Acquired Flashcards

1
Q

What is defined as a massive blood transfusion?

A

Transfusion of one’s entire blood volume within 24 hours, transfusion of half (50%) of total blood volume in 3 hours, transfusion of >10 units of packed red cells in 24 hours, or transfusion of >4 units in 1 hour.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

What deficiencies are typically found in stored blood?

A

Deficient in platelets and some coagulation factors (F V and VIII).

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

What causes haemostatic defects in massively transfused patients?

A

Dilution of platelets and coagulation factors.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

What is the major role of the liver in haemostasis?

A

Synthesizes coagulation factors and natural anticoagulants, utilizes vitamin K for synthesis of vitamin K dependent proteins, and clears activated coagulation factors and plasminogen activators.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

What are common causes of bleeding in liver disease?

A
  • Oesophageal varices (portal hypertension)
  • Thrombocytopenia
  • Deficient synthesis of coagulation factors
  • Deficient utilization of vitamin K
  • Disseminated intravascular coagulation (DIC)
  • Increased fibrinogenolysis
  • Defective platelet function
  • Synthesis of defective fibrinogens.
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

What laboratory findings are associated with liver disease?

A
  • Prolonged PT
  • Prolonged APTT
  • Prolonged TT
  • VWF normal
  • Low platelet.
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

What management strategies are recommended for liver disease-related bleeding?

A
  • Fresh frozen plasma
  • Prothrombin complex concentrate
  • Supply vitamin K dependent factors
  • Vitamin K
  • Fibrinolytic inhibitors if no DIC.
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

What is Vitamin K deficiency bleeding (VKDB)?

A

A condition where levels of vitamin K-dependent clotting factors are depressed in newborns, leading to bleeding.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

What are the presentations of early, classical, and late VKDB?

A
  • Early VKDB: First 24 hours of life
  • Classical VKDB: Days 2-7 of life
  • Late VKDB: Day 8 to 6 months of life.
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

What causes early VKDB?

A

Infants of mothers on vitamin K-inhibiting drugs.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

What is the diagnostic criterion for VKDB?

A

A Prothrombin Time (PT) more than four times control with a normal platelet count, normal fibrinogen level, and absent fibrinogen degradation products.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

What are the treatment options for VKDB?

A

Prophylaxis with oral vitamin K, IV vitamin K for active bleeding, and monitoring PT correction.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

What is the role of vitamin K in the body?

A

Vitamin K is a fat-soluble vitamin essential for synthesizing certain coagulation factors.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

What are common causes of vitamin K deficiency?

A
  • Haemorrhagic disease of the newborn
  • Poor dietary intake
  • Impaired absorption
  • Drugs like anticoagulants (e.g., Warfarin)
  • Broad-spectrum antibiotics.
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

What are specific inhibitors in coagulation disorders?

A

Antibodies that inhibit the activity of specific coagulation factors, including FVIII, FIX, fibrinogen, and von Willebrand factor.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

What is Acquired Haemophilia A?

A

A rare autoimmune bleeding disorder due to auto-antibodies against endogenous FVIII.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
17
Q

What are the clinical manifestations of Acquired Haemophilia A?

A
  • Widespread subcutaneous bleeding
  • Haematomas
  • GI and GU bleeding
  • Neurovascular compression may be limb-threatening.
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
18
Q

What is the pathogenesis of disseminated intravascular coagulation (DIC)?

A

Involves a fibrinolytic defect and the role of cytokines, with sepsis being the most common trigger.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
19
Q

What laboratory findings are indicative of acute DIC?

A
  • Prolonged PT, APTT, and TT
  • Reduced fibrinogen level
  • Increased D-Dimers/FDP
  • Reduced platelet count.
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
20
Q

What is the treatment for lupus anticoagulant?

A

Long-term anticoagulant therapy is frequently required in patients with thrombosis.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
21
Q

What are the types of antiphospholipid antibodies?

A
  • Anticardiolipin antibodies
  • Anti-b2-glycoprotein I antibodies
  • Lupus anticoagulant.
22
Q

What are common laboratory findings in chronic DIC?

A
  • PT, APTT normal
  • Platelet count normal
  • FDP and D-dimer increased.
23
Q

What is acquired von Willebrand syndrome associated with?

A

An autoantibody, typically in the context of monoclonal gammopathy or other hematological disorders.

24
Q

What is the significance of the presence of proteins induced by vitamin K absence or antagonism (PIVKA)?

A

It is a marker of subclinical vitamin K deficiency.

25
Q

What is the effect of anticoagulants like Warfarin on vitamin K?

A

They inhibit the enzyme epoxide reductase, preventing the recycling of vitamin K.

26
Q

What are the treatment options for acquired factor V deficiency?

A
  • Fresh frozen plasma
  • Platelets may be useful in resistant cases.
27
Q

What are the clinical manifestations of renal disease related to coagulation disorders?

A

Excessive urinary loss of factor IX and antithrombin III in nephrotic syndrome.

28
Q

What is the typical presentation of acquired protein S deficiency?

A

Patients present with skin necrosis and DIC.

29
Q

What triggers disseminated intravascular coagulation (DIC) among medical or surgical inpatients?

A

The production of endotoxin by the offending organism activates monocytes, provoking the release of endogenous tissue factor and inflammatory cytokines.

30
Q

What cytokines are involved in coagulation activation in DIC?

A

IL-6, IL-1, TNF-α

31
Q

What is immune thrombocytopenia (ITP)?

A

An acquired, autoimmune disorder with the formation of antiplatelet antibodies against platelets and megakaryocytes.

32
Q

What are the two phases of immune thrombocytopenia (ITP)?

A
  • Primary ITP: autoimmune disorder with isolated thrombocytopenia
  • Secondary ITP: all other forms of ITP except primary, e.g., drug-induced, associated with infections
33
Q

What is the threshold for ITP and clinical thrombocytopenia?

A

A platelet count <100 × 10^9/L

34
Q

What are common causes of thrombocytopenia?

A
  • Central (production failure)
  • Peripheral (reduced survival)
35
Q

What is a characteristic symptom of platelet defects?

A

Mucocutaneous bleeding

36
Q

What is the treatment for Scurvy, a vascular defect?

A

Vitamin C 200 mg daily

37
Q

What are the clinical features of Henoch-Schönlein purpura?

A
  • Abdominal colic
  • Arthritis
  • Nephritis
  • Palpable purpura
38
Q

What is the typical onset of acute ITP in children?

A

Abrupt onset of thrombocytopenia, often preceded by a viral illness.

39
Q

What is the female-to-male ratio for chronic ITP?

40
Q

What are the signs and symptoms of ITP?

A

Bleeding into the skin and mucosal surfaces (petechiae, ecchymoses)

41
Q

What laboratory findings are indicative of ITP?

A
  • Prolonged bleeding time
  • Normal PT and PTT
  • Low platelet count
42
Q

What is the goal of treatment for ITP?

A

To stop bleeding and increase platelet count to a safe level.

43
Q

What therapeutic agents are used for ITP?

A
  • Oral corticosteroids
  • IV immune globulin (IVIG)
  • IV anti-D immune globulin
  • Thrombopoietin receptor agonists (TPO-RA)
  • Rituximab
  • Fostamatinib
44
Q

What characterizes disseminated intravascular coagulation (DIC)?

A

Systemic activation of blood coagulation leading to microvascular thrombi and multiple organ dysfunction syndrome (MODS).

45
Q

What are common causes of DIC?

A
  • Gram-negative and meningococcal septicaemia
  • Severe falciparum malaria
  • Viral infections
  • Amniotic fluid embolism
  • Incompatible blood transfusion
46
Q

What are the three mechanisms characterizing the pathogenesis of DIC?

A
  • Intravascular activation of extrinsic pathway of coagulation
  • Reduction in levels of endogenous anticoagulants
  • Suppression of the fibrinolytic system
47
Q

What is hemostasis?

A

The mechanism that leads to cessation of bleeding from a blood vessel.

48
Q

What are the major components of hemostasis?

A
  • Procoagulant mechanisms
  • Anticoagulant mechanisms
  • Fibrinolysis
49
Q

What are the stages of hemostasis?

A
  • Constriction of the blood vessel
  • Formation of a temporary platelet plug
  • Activation of the coagulation cascade
  • Formation of fibrin plug or final clot
50
Q

What are the basic laboratory tests for diagnosing acquired bleeding disorders?

A
  • Partial thromboplastin time (PTT)
  • International normalized ratio (INR)
  • Full blood count with peripheral blood smear
51
Q

What are acquired bleeding disorders?

A

The most common causes of bleeding seen in hematology practice, due to interference with platelet plug formation or blood coagulation proteins.